Compare ABEO & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABEO | ESPR |
|---|---|---|
| Founded | 1974 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.0M | 898.5M |
| IPO Year | 1980 | 2013 |
| Metric | ABEO | ESPR |
|---|---|---|
| Price | $5.36 | $3.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $18.20 | $6.86 |
| AVG Volume (30 Days) | 1.8M | ★ 6.5M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | $400,000.00 | ★ $303,802,000.00 |
| Revenue This Year | N/A | $25.45 |
| Revenue Next Year | $1,590.36 | N/A |
| P/E Ratio | $4.16 | ★ N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $3.93 | $0.69 |
| 52 Week High | $7.54 | $4.13 |
| Indicator | ABEO | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 61.15 |
| Support Level | $4.53 | $3.72 |
| Resistance Level | $5.61 | $4.00 |
| Average True Range (ATR) | 0.26 | 0.26 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 78.90 | 75.24 |
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.